The size of the Genomics Market in MEA was worth USD 1.56 billion in 2023 and estimated to be growing at a CAGR of 11.29%, to reach USD 2.67 billion by 2028 during the forecast period.
Genomics is a discipline that analyses the function and structure of genomes. It uses various sampling, sequencing, data analysis, and interpretation techniques to decode, assemble and analyze genomes. Knowing the complete set of DNA helps identify certain genetic diseases, develop the best course of treatment, and contribute to precision medicine.
The genomics market is chiefly driven by the intensifying competition in the global pharmaceutical industry, increased use of genomics in research, and new drug classes. In addition, increased demand for genetically modified animals and plants and the constantly reducing prices of genetic procedures also lead to significant developments in the global genomics market through a rising scope for research and innovation.
However, the high cost of genomic instruments is one of the major restraints of the market.
This research report on the Middle East and Africa Genomics Market has been segmented & sub-segmented into the following categories:
By End User:
The MEA genomics market is projected to witness a considerable share in the global market during the forecast period owing to the growing prevalence of cardiovascular and genetic disorders across the MEA. Also, increasing applications over genomes and the growing scale of healthcare centers and diagnostic applications are expected to boost the market demand in the Middle East and Africa. Moreover, the major players in the region are focusing on developing advanced technology to handle the complex application simply, which is majorly influencing the market growth. As a result, South Africa, Saudi Arabia, and UAE significantly expand the MEA regional genomics market growth.
The South African genomics market is more likely to dominate the MEA market during the forecast period. The market growth is expected to be fuelled by the proliferation of diseases, the growing prevalence of effective treatment procedures, and the growing number of start-ups and such initiatives. However, some of the prominent players are investing in the research and developing activities on genomics, and the adoption of genomic centers further expands the market growth.
On the other hand, the emerging countries such as UAE and Saudi Arabia are projected to register a promising share in the genomics market during the forecast period owing to the growing preference for personalized medicine and the advent of DNA and gene microarray technologies has revolutionized the field of personalized medicine in these countries.
KEY MARKET PLAYERS:
Affymetrix, Inc., Agilent Technologies, BGI, Bio-Rad Laboratories Inc., GE Healthcare, Illumina Inc., Qiagen, Roche Diagnostics, Life Technologies, and Cepheid are playing a key role in the MEA genomics market.
Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2000
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: [email protected]